The SFTPA1 gene helps make surfactant protein A, a substance in the lungs that helps keep tiny air sacs stable and supports the immune system as you breathe in dust and germs. If it does not work properly, lung protection may be weaker, and some inherited variants are linked to scarring lung disease that can lead to cough, shortness of breath, and lower oxygen levels. This gene is mainly known in medical genetics rather than popular culture.
What is a gene?
Genes are stretches of DNA that carry instructions your cells use to make molecules or regulate processes in the body. Some genes hold the information needed to produce proteins, which are the working parts of cells. Others mainly guide when certain processes take place, where they occur, and how strongly they operate. Taken together, genes affect how the body develops and works, and they can also shape how you respond to food, stress, or medications. For a deeper look at this topic, you can find more in the LearnHub.
Overview
SFTPA1Gene function
What if the gene works
The SFTPA1 gene helps make surfactant protein A, a lung protein that helps keep tiny air sacs working well. It also supports the lungs’ early defense by helping recognize and clear inhaled germs and particles.
Risk
What if the gene does not work
Variants in the SFTPA1 gene can cause interstitial lung disease or pulmonary fibrosis, and some families also have lung adenocarcinoma. Milder and more severe variants may affect whether symptoms start in childhood or adulthood and how severe they are.
Treatment
What does that mean for your treatment
No established treatment or drug choice is currently specific to a pathogenic or loss of function variant in the SFTPA1 gene. Research is studying the SFTPA1 gene and related surfactant pathways as possible biomarkers in interstitial lung disease and lung cancer, but this has not led to guideline based, gene specific therapy.
Conditions associated with SFTPA1
Gene function
What if the gene works
Each breath depends on a thin, slippery coating that keeps the lung air sacs open and clean. The SFTPA1 gene helps make part of this coating, called surfactant protein A. This protein is a key part of the SFTPA1 gene's role in the lungs, where it supports smooth breathing and helps the airways respond to inhaled germs and particles.
Its protein helps organize surfactant, the fatty coating that lines the tiny air sacs. This supports even spreading of that coating so the lungs can inflate and deflate with less effort.
The protein can attach to certain germs and inhaled particles in the airways. This helps lung immune cells recognize, collect, and clear them from the breathing passages.
This protein also helps shape a measured immune response in the lungs. It can support defense signals while helping limit extra inflammation in delicate air sacs.
In daily breathing, this protein supports the normal recycling and cleanup of used surfactant material. That helps keep the air sac coating ready to work with each breath.
What is a variant?
A genetic variant is a small change in the DNA sequence within a gene. These changes are common and are part of normal human diversity, including differences in appearance, metabolism, and how the body responds to environmental influences. Many variants do not have any noticeable effect and simply represent natural genetic variation. In some situations, though, a variant can change how a gene functions more significantly and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Many SFTPA1 gene variants make the surfactant protein fold poorly, get trapped inside lung cells, or break down too easily, reducing the amount that reaches the air sacs. For people reading about how SFTPA1 gene variants affect protein function, milder variants may leave partial activity, while more disruptive variants can cause marked loss of stability or secretion. This range can help explain why SFTPA1-related interstitial lung disease appears at different ages and with varying severity.
How variants are linked to conditions
Pathogenic variants in the SFTPA1 gene cause familial pulmonary fibrosis, an inherited form of interstitial lung disease. People with SFTPA1-related lung disease may develop lung scarring in adulthood, though the age it starts and how much it affects breathing can vary. In some families, these variants have also been associated with a higher risk of lung adenocarcinoma.
A variant is not necessarily a diagnosis
Gene variants are a routine part of human biology and are common throughout the general population. Most do not have a direct effect on health and simply reflect natural human diversity. For many genes, carrying a variant associated with a condition suggests a possible link rather than a definite diagnosis, especially when several genes and environmental factors play a role. In some cases, though, a single well-characterized variant in a specific gene can be enough to confirm a diagnosis.
Are there things that can increase or change my risk?
There is not yet broadly confirmed evidence on specific factors that increase or reduce risk related to the SFTPA1 gene. For families with an SFTPA1 change linked to lung disease, smoking and other lung irritants can still add stress to the lungs, so avoiding them and keeping up with medical follow-up is important.
Inheritance of SFTPA1 variants
SFTPA1-related conditions are usually inherited in an autosomal dominant pattern. In practical terms, how SFTPA1 gene variants are inherited means that a parent with a disease-causing variant can pass it to a son or daughter, and each child has a 50% chance of inheriting that variant. Men and women are affected and can pass it on equally, because the SFTPA1 gene is on chromosome 10 rather than a sex chromosome. Not everyone who inherits a variant will be affected in the same way.
What does my SFTPA1 result mean for my family?
For some SFTPA1-related lung conditions, the pattern is usually dominant, which means close relatives like parents, brothers, sisters, and children may also carry the same gene change. In practical terms, a family result can matter beyond one person, especially in families where several relatives have had scarring in the lungs or certain lung cancers. Some cases can start as a new gene change in one person, so a parent is not always the source.
Genetic information
Genetic testing
How you find out about variants
To find out whether you carry a variant in the SFTPA1 gene, a lab can analyze DNA from a blood sample, saliva sample, or cheek swab. Genetic testing for SFTPA1 variants reads the gene’s sequence and compares it with the usual pattern to look for changes, which may be reported as benign, uncertain, or clinically significant.
When should I consider getting a genetic test?
SFTPA1 testing may be considered when several family members have unexplained lung scarring, also called pulmonary fibrosis, especially if it starts earlier than usual or occurs along with lung cancer in the family. Testing decisions are best made with a doctor or genetic counselor, often as part of a broader lung disease gene panel.
A genetic result is only one part of your health story
Genetic results can be informative, but how much they explain depends on the condition and the specific type of variant. Many factors, including lifestyle, environment, age, and medical history, shape how the body functions over time. For some conditions, especially those influenced by many genes, genetic information provides context rather than certainty and is best understood alongside other parts of care. In other situations, a genetic result may offer a clear answer. In areas like medication response, genetic results can also help put individual experiences into perspective.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Small differences in DNA can change how the body breaks down a drug, moves it through the body, or responds to it at its target. This helps explain why the same medication works well for one person, works less well for another, or causes more side effects in someone else.
What is Pharmacogenetics?
Pharmacogenetics examines how inherited genetic differences can affect the way people respond to medications. It studies gene drug patterns to better explain why the same treatment may work differently from one person to another. For many medicines, genes can influence how powerfully a drug works or how the body handles it. This information can help guide more informed, personalized treatment decisions. More detail on this topic is available in the LearnHub.
Drugs influenced by the SFTPA1 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medication choice or dose. If you have concerns about breathing symptoms, lung conditions, side effects, or how a medicine is affecting you, talk with your doctor or pharmacist.
History
Researchers began clarifying the history of the SFTPA1 gene in the late 20th century, as studies of lung surfactant showed that its proteins do more than keep air sacs open. From these first observations, research expanded steadily, and scientists recognized that human surfactant protein A comes from two closely related genes, the SFTPA1 gene and the SFTPA2 gene. This helped explain why earlier laboratory findings about surfactant protein A sometimes looked more complex than expected. As genetic methods improved, the SFTPA1 gene was mapped and sequenced, allowing clearer study of inherited differences between people. Its history is mainly tied to advances in lung biology and newborn medicine rather than to a single public event or famous case.